COMMUNIQUÉS West-GlobeNewswire

Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer
04/03/2026
Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer Competitive funding award highlights Theolytics’ innovative [...]
Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments
04/03/2026
March 4, 2026 CE Marked and 510(k) pending, Rembra’s advanced image reconstruction technology delivers up to 106 images per second [1] and a high throughput of up to 270 patients per day [2] to support faster diagnosis [...]
New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors
04/03/2026
ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer EUR neffy ® —the first and [...]
RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS
04/03/2026
LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
From Pain to Prevention: How Dubai’s Urologist is Saving Kidneys and Lifestyles
04/03/2026
Dr. Kamalesh, Urologist in Dubai, Shares Essential Tips for Preventing Kidney Stones in the UAE Climate DUBAI, United Arab Emirates, March 04, 2026 (GLOBE NEWSWIRE) -- As temperatures remain a focal point for residents [...]
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
04/03/2026
BASEL, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data. BV100 demonstrated a dose- [...]
Independent study presented at ECR highlights REGENERA™ bioresorbable scaffold potential for breast restoration after lumpectomy
04/03/2026
Independent investigators from the University of Pisa presented new data at the 2026 European Congress of Radiology (ECR) Ultrasound follow-up documented predictable scaffold bioresorption and progressive soft-tissue [...]
Réaction aux attaques visant Carbios et ses dirigeants
04/03/2026
Clermont-Ferrand (France), 4 mars 2026 (08h45 CET). Carbios (Euronext Growth Paris : ALCRB) dénonce la campagne de déstabilisation dont elle fait l’objet depuis plusieurs mois et conteste formellement l’ensemble des [...]
Response to attacks against Carbios and its executives
04/03/2026
Clermont-Ferrand (France), March 4, 2026 (8:45 a.m. CET). Carbios (Euronext Growth Paris : ALCRB) denounces the destabilization operation to which it has been subjected for several months and formally contests all [...]
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
04/03/2026
REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
04/03/2026
REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients [...]
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
04/03/2026
— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — — Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March [...]
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
04/03/2026
Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ® Phase 3 trial of daridorexant [...]
AudiLeaf Ear Health Claims Evaluated: 2026 Report Examines Ingredients, Proprietary Blend Dosing, and What Consumers Should Verify Before Buying
04/03/2026
A 2026 informational consumer evaluation of AudiLeaf's ear health marketing claims, proprietary herbal blend ingredient research context, pricing structure, and what to verify before purchasing Aurora, CO, March 03, [...]
Male Power XL "Black Elixir" Claims Evaluated: 2026 Report Examines Ingredient Research, Proprietary Blend Transparency, and What Men Should Verify Before Buying
04/03/2026
A 2026 informational consumer report evaluating Male Power XL's "black elixir" marketing language, ingredient research context, proprietary blend limitations, pricing and policy terms shown on the official site, and [...]
MemoTril Cognitive Support Claims Evaluated: Latest 2026 Consumer Report Examines MemoTril Brain Supplement Ingredients, Memory Enhancement Marketing, and What Consumers Should Verify
04/03/2026
Informational 2026 consumer report examining MemoTril brain supplement ingredients, cognitive support marketing claims, ingredient research context, pricing disclosures, and what consumers should verify before [...]
DermaFix Nail Fungus Treatment Gel Claims Evaluated in 2026 Market Report Covering Tea Tree Oil Research, Penetration Technology Positioning, and Pricing Transparency
04/03/2026
An informational industry analysis examining ingredient-level research, marketing positioning trends, regulatory context, and publicly listed pricing structures in the topical nail fungus category Sheridan, WY, March 03 [...]
Vaxart to Host Upcoming Conference Calls
03/03/2026
Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2026 ( [...]
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/03/2026
NEW YORK and WALTHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]

Pages